Plain-English translation of NCT05321706 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Heart transplant recipients often develop kidney problems over time due to the medications they need to take to prevent rejection. This trial is testing whether a medication called dapagliflozin can help protect the kidneys and slow this damage. Half of the participants will receive the medication for one year, and half will receive a placebo (a dummy pill with no active ingredient).
After a heart transplant, the immune-suppressing drugs that prevent rejection can gradually harm the kidneys, causing them to work less well over the years. Researchers want to know if this medication can help slow or prevent this kidney damage, which could help transplant recipients live healthier, longer lives.
You would take one tablet by mouth once a day for one year — either the study medication or a placebo, decided by random assignment. You'll likely have regular clinic visits to have your kidney function checked with blood tests and to make sure the treatment is safe and working. The study lasts one year, and you would continue your regular heart transplant care throughout.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
Netherlands
Norway
Sweden